SARS-CoV-2 Seroconversion and Pregnancy Outcomes in a Population of Pregnant Women Recruited in Milan, Italy, between April 2020 and October 2020

Veronica Accurti, Bianca Gambitta, Simona Iodice, Alessandro Manenti, Simona Boito, Francesca Dapporto, Margherita Leonardi, Eleonora Molesti, Isabella Fabietti, Emanuele Montomoli, Valentina Bollati and Nicola Persico ()
Additional contact information
Veronica Accurti: Fetal Medicine and Surgery Service, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Bianca Gambitta: Fetal Medicine and Surgery Service, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Simona Iodice: EPIGET Lab, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
Alessandro Manenti: VisMederi Srl, 53100 Siena, Italy
Simona Boito: Fetal Medicine and Surgery Service, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Francesca Dapporto: VisMederi Srl, 53100 Siena, Italy
Margherita Leonardi: VisMederi Srl, 53100 Siena, Italy
Eleonora Molesti: VisMederi Srl, 53100 Siena, Italy
Isabella Fabietti: Fetal Medicine and Surgery Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Emanuele Montomoli: VisMederi Srl, 53100 Siena, Italy
Valentina Bollati: EPIGET Lab, Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
Nicola Persico: Fetal Medicine and Surgery Service, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy

IJERPH, 2022, vol. 19, issue 24, 1-13

Abstract: The possible link between SARS-CoV-2 infection and adverse pregnancy outcomes has so far demonstrated heterogeneous results in terms of maternal, fetal, and neonatal complications. We aim to investigate the correlation between SARS-CoV-2 seroconversion and/or neutralization titer and pregnancy outcomes. We analyzed a population of 528 pregnant women followed up from the first trimester of gestation until delivery. For each woman, we collected a first blood sample between 11 and 13 weeks of gestation and a second sample in the perinatal period (between peripartum and puerperium) to assess the presence of SARS-CoV-2 antibodies and/or microneutralization titer (MN titer). Data on pregnancy outcomes (gestational age at delivery, preterm birth before 34 weeks, hypertensive disorders, gestational diabetes, and abnormal fetal growth) were collected. We observed that serologic status per se is not associated with major pregnancy complications. On the contrary, the MN titer was associated with increased odds of gestational diabetes. Although we mainly reported asymptomatic SARS-CoV-2 infections and the absence of severe maternal and neonatal adverse outcomes, SARS-CoV-2 infection might challenge the maternal immune system and explain the moderate increase in adverse outcome odds.

Keywords: SARS-CoV-2; antibodies; neutralization titer; pregnancy outcomes; preterm birth hypertensive disorders; gestational diabetes; abnormal fetal growth (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/24/16720/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/24/16720/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:24:p:16720-:d:1001806

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().